Webcast to be held Monday, September 23, at 8:00 a.m. ET
CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: NASDAQ:), a clinical-stage oncology firm creating MasterKey therapies that focus on households of oncogenic mutations in sufferers with most cancers, will host a webcast to reveal preliminary part 2 medical trial outcomes for BDTX-1535 in sufferers with recurrent EGFRm NSCLC on Monday, September 23, 2024, at 8:00am ET.
Webcast info
The webcast could be accessed underneath Occasions and Displays on the Traders part of the Black Diamond web site at www.blackdiamondtherapeutics.com. A replay of the webcast might be out there following the completion of the occasion.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology firm creating MasterKey therapies that focus on households of oncogenic mutations in sufferers with most cancers. The Firm’s MasterKey therapies are designed to handle a broad spectrum of genetically outlined tumors, overcome resistance, decrease wild-type mediated toxicities, and be mind penetrant to deal with CNS illness. The Firm is advancing two clinical-stage applications: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor concentrating on EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor concentrating on KRAS, NRAS and BRAF alterations in strong tumors. For extra info, please go to www.blackdiamondtherapeutics.com.
Contacts
For Traders:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
[email protected]
For Media:
[email protected]
